Ionis Pharmaceuticals Announced Topline Data From HALOS Phase 1/2A Open-label Study Of ION582 In Angelman Syndrome, ION582 Was Safe And Well Tolerated In The Study And Showed Encouraging And Consistent Benefits
Ionis Pharmaceuticals Announced Topline Data From HALOS Phase 1/2A Open-label Study Of ION582 In Angelman Syndrome, ION582 Was Safe And Well Tolerated In The Study And Showed Encouraging And Consistent Benefits
Ionis Pharmaceuticals 公佈了 HALOS 針對 ION582 的 1/2A 期開放標籤研究的主要數據，該研究顯示 ION582 安全且耐受性良好，並顯示出令人鼓舞且持續的益處
- ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients
- ION582 was safe and well tolerated at all dose levels
- Ionis plans to move ION582 into pivotal trial
- Detailed ION582 data to be presented at upcoming medical meeting
- ION582 顯示 Angelman 綜合徵患者的多個功能領域持續改善
- ION582 在所有劑量水平下均安全且耐受性良好
- Ionis 計劃將 ION582 轉入關鍵試驗
- 詳細的 ION582 數據將在即將舉行的醫學會議上公佈
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。